Clinical case of treatment of secondary chondrosarcoma developed due to Ollier disease
M. M. Zamilov,
K. V. Menshikov,
Sh. I. Musin,
A. V. Sultanbayev,
I. A. Sharifgaliev,
S. V. Osokin,
V. S. Chalov https://doi.org/10.17650/2219-4614-2023-15-1-66-71
Abstract
Ollier disease is a rare non-hereditary disorder of the bone tissue characterized by development of multiple benign bone tumors – enchondromas. One of the dangerous complications of this pathology is tumor transition into chondrosarcoma. Currently, there are no drug therapies for Ollier disease. Surgical treatment is performed in case of complications (chondrosarcoma, pathological fracture).
The article presents a clinical case of chondrosarcoma treatment in a 42-year-old male with Ollier disease diagnosed when the patient was 8 years old. Since 2021, the patient noted intensive tumor growth on the right foot and left calf. In August of 2022, the patient sought medical help at the Republican Clinical Oncological Dispensary of the Bashkortostan Ministry of Health. Examination showed synchronous malignant transformation of enchondromas of the right foot and left calf confirmed by histological exam. Due to tumor advancement, surgical treatment was performed. Other enchondroma lesions are being watched.
About the Authors
M. M. Zamilov
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Bashkortostan
Russian Federation
Russian Federation
Marat M. Zamilov.
73/1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan
K. V. Menshikov
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Bashkortostan; Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
73/1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan; 3 Lenin St., Ufa 450008, Republic of Bashkortostan
Sh. I. Musin
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Bashkortostan; Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
73/1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan; 3 Lenin St., Ufa 450008, Republic of Bashkortostan
A. V. Sultanbayev
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Bashkortostan
Russian Federation
Russian Federation
73/1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan
I. A. Sharifgaliev
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Bashkortostan; Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
73/1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan; 3 Lenin St., Ufa 450008, Republic of Bashkortostan
S. V. Osokin
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Bashkortostan
Russian Federation
Russian Federation
73/1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan
V. S. Chalov
Republican Clinical Oncological Dispensary, Ministry of Health of Republic of Bashkortostan
Russian Federation
Russian Federation
73/1 Prospekt Oktyabrya, Ufa 450054, Republic of Bashkortostan
References
1. Silve C., Juppner H. Ollier disease. Orphanet J Rare Dis 2006;1:37. DOI: 10.1186/1750-1172-1-37
2. Amary M.F., Damato S., Halai D. et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. DOI: 10.1038/ng.994
3. Chang D., Wei C., Fujun L. et al. Skull base chondrosarcoma caused by Ollier disease: a case report and literature review. World Neurosurg 2019;127:103–8. DOI: 10.1016/j.wneu.2019.03.037
4. El Abiad J.M., Robbins S.M., Cohen B. et al. Natural history of Ollier disease and Maffucci syndrome: patient survey and review of clinical literature. Am J Med Genet A 2020;182(5):1093–103. DOI: 10.1002/ajmg.a.61530
5. Kumar A., Jain V.K., Bharadwaj M., Arya R.K. Ollier disease: pathogenesis, diagnosis, and management. Orthopedics 2015;38(6):e497–506. DOI: 10.3928/01477447-20150603-58
6. The state of cancer care for the population of Russia in 2022. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2020. 239 p. (In Russ.).
7. Godkin O., Ellanti P., O’Toole G. Ollier’s disease: features of the hands. BMJ Case Rep 2017;2017:bcr2017220009. DOI: 10.1136/bcr-2017-220009
8. D’Angelo L., Massimi L., Narducci A., Di Rocco C. Ollier disease. Childs Nerv Syst 2009;25(6):647–53. DOI: 10.1007/s00381-009-0873-z
9. Verdegaal S.H.M., Bovee J.V.M.G., Pansuriya T.C. et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with ollier disease and maffucci syndrome: an international multicenter study of 161 patients. Oncologist 2011;16(12):1771–9. DOI: 10.1634/theoncologist.2011-02
10. Ranger A., Szymczak A. Do intracranial neoplasms differ in Ollier disease and Maffucci syndrome? An in-depth analysis of the literature. Neurosurgery 2009;65(6):1106–13. DOI: 10.1227/01.NEU.0000356984.92242.D5
11. Jaffe H.L., Lichtenstein L. Solitary benign enchondroma of bone. Arch Surg 1943;46:480–93.
12. Herget G.W., Strohm P., Rottenburger C. et al. Insights into enchondroma, enchondromatosis and the risk of secondary chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up. Neoplasma 2014;61(4):365–78. DOI: 10.4149/neo_2014_046
13. Kattepur A.K., Jones R.L., Gulia A. Dedifferentiated chondrosarcoma: current standards of care. Future Oncol 2021;17(35):4983–91. DOI: 10.2217/fon-2021-0830
14. Diezi M., Zambelli P.-Y., Superti-Furga A. et al. Cancer surveillance in children with Ollier Disease and Maffucci Syndrome. Am J Med Genet A 2021;185(4):1338–40. DOI: 10.1002/ajmg.a.62078
Review
For citations:
Zamilov M.M., Menshikov K.V., Musin Sh.I., Sultanbayev A.V., Sharifgaliev I.A., Osokin S.V., Chalov V.S. Clinical case of treatment of secondary chondrosarcoma developed due to Ollier disease. Bone and soft tissue sarcomas, tumors of the skin. 2023;15(1):66-71. (In Russ.) https://doi.org/10.17650/2219-4614-2023-15-1-66-71
Views:
271
Email this article 
